Skip to main content
MedPathMedPath Home
Clinical Trials/CTRI/2019/01/017219
CTRI/2019/01/017219
Recruiting
未知

Realtime Enrichment Screen for Outright detection of Latent Undiagnosed malignant Tumors in asymptomatic individuals Efficiently - RESOLUTE

Datar Cancer Genetics Limited0 sites0 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsHealth Condition 1: C00-D49- Neoplasms

Overview

Phase
未知
Intervention
Not specified
Conditions
Health Condition 1: C00-D49- Neoplasms
Sponsor
Datar Cancer Genetics Limited
Status
Recruiting
Last Updated
3 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
3 years ago
Study Type
Observational

Investigators

Sponsor
Datar Cancer Genetics Limited

Eligibility Criteria

Inclusion Criteria

  • •Non\-cancer arm\-
  • •For Inclusion, an individual must meet all of the following criteria:
  • •1\.Age â?? 49 to 75 years for males and 40 to 75 years for females
  • •2\.Participants with no known diagnosis or past history of cancer
  • •3\.Willingness to provide blood sample as per study protocol
  • •4\.Patient should be willing for screening investigations proposed in study protocol.
  • •5\.Female patient is not pregnant / lactating (self\-report)
  • •6\.Provision of signed informed consent form and expresses understanding of the protocol and its requirements, risks, and discomforts.
  • •7\.Stated willingness to comply with all study procedures
  • •Cancer arm\-

Exclusion Criteria

  • •Non\-cancer arm\-
  • •For Exclusion, an individual may meet any of the following criteria:
  • •1\.Known current or prior diagnosis of cancer
  • •2\.Unable to provide informed consent
  • •3\.Unable to comply with all project screening procedures
  • •4\.Current treatment with any investigational drug or intervention
  • •5\.Pregnant or lactating women (by self\-report)
  • •6\.Age less than 49 or more than 75 years for males and less than 40 or more than 75 years for females
  • •7\.Unable/unwilling to provide blood sample as per study requirement.
  • •8\.Oral or IV corticosteroid use in past 14 days prior to blood draw

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Not Applicable
ColoVision: Using computers to instantly find and describe colorectal polyps
ISRCTN68236490Portsmouth Hospitals NHS Trust654
Recruiting
Not Applicable
A fully-automated rapid detection system for detecting PNPLA3 (rs738409) single nucleotide polymorphisms associated with the prognosis of fatty liverfatty liver
JPRN-UMIN000024021Saga-Ken Medical Centre Koseikan100
Not yet recruiting
Not Applicable
Evaluation of a real-time computer aided detection and diagnosis system of Barrett's neoplasia during live endoscopic procedures: A multicenter prospective study10017990Esophageal Adenocarcinomaesophageal cancer10017991
NL-OMON56957Academisch Medisch Centrum200
Not yet recruiting
Not Applicable
INTRAOPERATIVE REAL TIME IMAGING WITH A DUAL RADIOACTIVE/FLUORESCENCE MODALITY FOR SENTINEL NODE LOCALIZATION. A FEASIBILITY STUDY INCLUDING REPRODUCIBILITY OF MULTIMODALITY LYMPHATIC MAPPING WITH A COCKTAIL TRACER CONTAINING 99mTc NANOCOLLOID /ICGmalignancy10027655
NL-OMON33218Antoni van Leeuwenhoek Ziekenhuis40
Completed
Phase 4
An active surveillance to monitor the real world safety of Nintedanib in Indian Idiopathic Pulmonary Fibrosis (a type of lung disease in which tissue deep in our lungs becomes thick and stiff, or scarred, over the time) patientsHealth Condition 1: null- Idiopathic Pulmonary Fibrosis
CTRI/2017/02/007867Boehringer Ingelheim India Pvt Ltd21